Role evidence
Usage summary
Strongest role: Inclusion Required
Inclusion-required count: 37
Treatment-assignment count: 0
Stratification count: 0
Cdx Established Context
EGFR mutation
NSCLC · Immune Checkpoint Inhibitor
EGFR mutation is flagged as cdx established context because public trials show inclusion required evidence in 37 contexts. FDA CDx context exists.
Threshold snippets
Fragmentation view
Threshold count: 19
Common snippets: PD-L1 TPS ≥50% | MSI-H | PD-L1 TPS >50%
Threshold label: Moderate
FDA CDx context
Mapping summary
CDx label: Fda Cdx Context Exists
CDx maturity score: 5/5
Confidence: High
Patent-density signal
Diagnostic appendix
Signal count: 0
Recent signals: 0
Density label: Low
Source links
Evidence paths
https://clinicaltrials.gov/study/NCT06364917 | https://clinicaltrials.gov/study/NCT04013542 | https://clinicaltrials.gov/study/NCT03225664 | https://clinicaltrials.gov/study/NCT03516981 | https://clinicaltrials.gov/study/NCT03242915 | https://clinicaltrials.gov/study/NCT07360743 | https://clinicaltrials.gov/study/NCT05579366 | https://clinicaltrials.gov/study/NCT02194738 | https://clinicaltrials.gov/study/NCT07111520 | https://clinicaltrials.gov/study/NCT02323126 | https://clinicaltrials.gov/study/NCT03564197 | https://clinicaltrials.gov/study/NCT07285434 | https://clinicaltrials.gov/study/NCT03447678 | https://clinicaltrials.gov/study/NCT06119581 | https://clinicaltrials.gov/study/NCT03948763 | https://clinicaltrials.gov/study/NCT06890598 | https://clinicaltrials.gov/study/NCT06447662 | https://clinicaltrials.gov/study/NCT04967417 | https://clinicaltrials.gov/study/NCT06711900 | https://clinicaltrials.gov/study/NCT06687369 | https://clinicaltrials.gov/study/NCT04619797 | https://clinicaltrials.gov/study/NCT04274907 | https://clinicaltrials.gov/study/NCT03215706 | https://clinicaltrials.gov/study/NCT02382406 | https://clinicaltrials.gov/study/NCT04623775 | https://clinicaltrials.gov/study/NCT03664024 | https://clinicaltrials.gov/study/NCT03304093 | https://clinicaltrials.gov/study/NCT02955290 | https://clinicaltrials.gov/study/NCT03275597 | https://clinicaltrials.gov/study/NCT04521075 | https://clinicaltrials.gov/study/NCT03836352 | https://clinicaltrials.gov/study/NCT06362369 | https://clinicaltrials.gov/study/NCT05061017 | https://clinicaltrials.gov/study/NCT03083691 | https://clinicaltrials.gov/study/NCT04267848 | https://clinicaltrials.gov/study/NCT03468985 | https://clinicaltrials.gov/study/NCT06908993